The Flec-SL trial
Initiatives
-
A randomized trial to test the hypothesis that short-term pharmacological reversal of electrical remodeling after cardioversion is equally efficient to prevent recurrent atrial fibrillation as standard long-term antiarrhythmic therapy.
- Start Year
- 2005
- End Year
- 2011
Visit The Flec-SL trial
| Investigators | Contacts |
|---|---|
|
Design
- Study design
- Patients' cohort
Marker Paper
Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial [published correction appears in Lancet. 2012 Oct 13;380(9850):1308]. Lancet. 2012;380(9838):238-246. doi:10.1016/S0140-6736(12)60570-4
PUBMED 22713626
Recruitment
- Sources of Recruitment
-
- Individuals
Number of participants
- Number of participants
- 760
- Number of participants with biosamples
Access
Availability of data and biosamples
| Data | |
| Biosamples | |
| Other |